Handelsbanken Fonder AB Purchases Shares of 160,900 Oruka Therapeutics, Inc. $ORKA

Handelsbanken Fonder AB bought a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 160,900 shares of the company’s stock, valued at approximately $15,313,000. Handelsbanken Fonder AB owned approximately 0.27% of Oruka Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Viking Global Investors LP bought a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $51,280,000. Paradigm Biocapital Advisors LP bought a new position in shares of Oruka Therapeutics in the fourth quarter valued at $51,840,000. Remedium Capital Partners LLC acquired a new position in Oruka Therapeutics during the fourth quarter worth $47,054,000. Deep Track Capital LP increased its holdings in Oruka Therapeutics by 38.4% during the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after buying an additional 735,983 shares during the last quarter. Finally, State Street Corp raised its position in Oruka Therapeutics by 112.2% during the fourth quarter. State Street Corp now owns 1,383,847 shares of the company’s stock worth $41,944,000 after acquiring an additional 731,819 shares in the last quarter. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Stock Performance

Shares of ORKA opened at $108.12 on Friday. Oruka Therapeutics, Inc. has a 52 week low of $14.08 and a 52 week high of $109.42. The firm has a market cap of $7.16 billion, a P/E ratio of -53.26 and a beta of -0.34. The firm’s 50-day simple moving average is $86.50 and its 200 day simple moving average is $62.27.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, equities analysts forecast that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Insider Transactions at Oruka Therapeutics

In other Oruka Therapeutics news, Director Carl Dambkowski sold 105,000 shares of the company’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $58.97, for a total value of $6,191,850.00. Following the transaction, the director directly owned 73,743 shares of the company’s stock, valued at $4,348,624.71. This represents a 58.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,290 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $59.07, for a total value of $607,830.30. Following the completion of the transaction, the senior vice president directly owned 16,406 shares in the company, valued at approximately $969,102.42. This represents a 38.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 181,406 shares of company stock worth $11,586,733 in the last ninety days. 23.49% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have commented on ORKA. Wedbush reiterated an “outperform” rating and issued a $165.00 price target on shares of Oruka Therapeutics in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 target price on shares of Oruka Therapeutics in a report on Monday, August 3rd. Guggenheim reiterated a “buy” rating and issued a $200.00 target price on shares of Oruka Therapeutics in a research note on Tuesday. UBS Group lifted their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Finally, Leerink Partners set a $120.00 price objective on Oruka Therapeutics in a research note on Thursday, April 30th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $134.30.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.